We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Summit Therapeutics Plc | SUMM | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 20.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 20.50 | 20.50 |
| Top Posts |
|---|
Posted at 15/9/2021 11:10 by chrisatrdg I have finally Sold out did so last week with a profit margin after many years invested & have risked all on INFA - fingers crossed.PS I will still keep an eye on SUMM |
Posted at 07/10/2019 13:06 by someuwin Summit Therapeutics plc Summit Therapeutics Reports New Data From Phase 2 Clinical Trial Connecting Ridinilazole's Microbiome...07/10/2019 12:00pm UK Regulatory (RNS & others) TIDMSUMM Summit Therapeutics plc ('Summit' or the 'Company') Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole's Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection -- Data Presented at ID Week 2019 Oxford, UK, and Cambridge, MA, US, 7 October 2019 -- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced the presentation of new data that explain the link between two key findings in the Company's Phase 2 clinical trial of ridinilazole for C. difficile infection ('CDI'): -- Ridinilazole demonstrated superior efficacy compared to vancomycin, driven by a 60% lower recurrence rate. -- Ridinilazole preserved the diversity of the gut microbiome. Researchers at Tufts University, collaborating with Summit, showed that these findings are connected mechanistically by bile acids, part of the 'metabolome' of active chemicals made or modified by gut bacteria. Bile acids exist in different forms that can either favour or block the regrowth of C. difficile after treatment. Vancomycin kills bacteria that turn pro-C. difficile bile acids into anti-C. difficile bile acids -- leaving an adverse ratio of pro- and anti-growth chemicals that favours the regrowth of C. difficile and the recurrence of C. difficile infection. By contrast, ridinilazole leaves these bacteria unharmed, allowing them to keep converting pro-C. difficile bile acids into anti-C. difficile bile acids, maintaining a positive chemical balance that prevents C. difficile recurrence. "The damaging effect of broad-spectrum antibiotics in the treatment of CDI is far-reaching from the make-up and function of the gut microbiome through the poor clinical outcomes seen in one third of patients, driven by a high rate of disease recurrence," said Dr David Roblin, President of R&D of Summit. "Ridinilazole has the potential to be a targeted CDI treatment that could result in significantly better patient outcomes for the over half million US patients per year who have an episode of CDI. These latest data help to put the science behind the function of a healthy microbiome into context and highlight its importance in sustaining CDI cures." The Phase 2 clinical trial enrolled 100 patients, half of whom received ridinilazole and the other half vancomycin. For both groups, there was a higher ratio of pro-C. difficile to anti C.-difficile bile acids at the start of treatment. This was expected, as patients who get CDI have perturbed microbiomes. However, during treatment, the proportion of anti-C. difficile bile acids increased in patients treated with ridinilazole, whereas patients treated with vancomycin initially showed decreases in anti-C. difficile bile acids and had stools dominated by pro-C. difficile bile acids. By the end of treatment, ridinilazole-treated patients' bile acid ratios returned towards a healthy, non-CDI state. These results support the data from the Phase 2 clinical trial, in which patients receiving ridinilazole showed a statistically significant improvement in sustained clinical responses. Copies of the two poster presentations are available in the Publications section of Summit's website, www.summitplc.com. |
Posted at 17/7/2019 12:09 by kirk 6 Summit Therapeutics plc Summit Highlighted Potential Of Smt-571 To Combat The Rising Global Health Threat Of Gonorrhoea At St...Source: UK Regulatory (RNS & others) TIDMSUMM Summit Therapeutics plc ('Summit' or the 'Company') Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress Oxford, UK, and Cambridge, MA, US, 17 July 2019 -- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it highlighted the potential of its preclinical new class antibiotic, SMT-571, to treat all gonorrhoea, including multi-drug and extensively-drug resistant strains, in a poster presentation at the STI & HIV World Congress in Vancouver, Canada. "The problem of gonorrhoea resistance is very concerning, and if nothing is done, physicians could see more and more cases of untreatable disease, " said Dr David Roblin, President of R&D of Summit. "As shown by the preclinical data presented, our gonorrhoea-targeted new class antibiotic, SMT-571, has the potential to overcome known resistance mechanisms across global isolates, including multi- and extensively-drug resistant strains. Further, there is a clear need for new gonorrhoea treatment options that would allow ceftriaxone to be reserved for the multitude of other serious infections that rely on its potency." Infections caused by the bacteria Neisseria gonorrhoeae are a growing global healthcare problem, with an estimated 78 million new cases globally per year. Infection rates continue to rise sharply as highlighted by the Centers for Disease Control and Prevention ('CDC'), which reported a 19% increase in US gonorrhoea cases in 2017, and Public Health England, which reported a 26% increase in the UK in 2018. Of great concern is the increase in resistance towards the current standard of care treatment for gonorrhoea, a combination of the broad-spectrum antibiotics, azithromycin and ceftriaxone. N. gonorrhoeae resistance rates to azithromycin are 4.4% and rising, and there is an emergence of resistance to ceftriaxone in these same strains, which are referred to as cases of 'super gonorrhoea.' Summit's poster featured preclinical data showing SMT-571 to be highly potent against 262 clinical strains of N. gonorrhoeae. This comprehensive panel of gonorrhoea strains, obtained from 1991 to 2018, was selected to be geographically and genetically diverse and include strains that are multi- and extensively-drug resistant. SMT-571 had a minimum inhibitory concentration range of 0.064 mg/L to 0.125 mg/L against the strains, including those with reduced susceptibility to ceftriaxone. Significantly, SMT-571 did not show cross-resistance with any antibiotic currently or previously used to treat gonorrhoea infections. A copy of the poster is available on the Company's website: https://www.globenew |
Posted at 18/6/2019 12:08 by kirk 6 Summit Therapeutics plc Increased Barda Award And Option ExerciseSource: UK Regulatory (RNS & others) TIDMSUMM Summit Therapeutics plc ('Summit' or the 'Company') Summit Announces BARDA Increases Award for Ridinilazole Clinical and Regulatory Development to up to $63.7 Million and Exercises Next Contract Option -- Summit Awarded $9.6M under Next Contract Option -- Total Committed BARDA Funding Now $53.6 Million Oxford, UK, and Cambridge, MA, US, 18 June 2019 -- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today announces that the Biomedical Advanced Research and Development Authority ('BARDA') has increased the total value of its award for the clinical and regulatory development of Summit's precision antibiotic ridinilazole for the treatment of C. difficile infection ('CDI') to up to $63.7 million. Under this award, BARDA has opted to exercise the next contract option for $9.6 million, which will support patient enrolment and dosing in the ongoing Phase 3 clinical trials of ridinilazole. "The funding from BARDA is a testament to the promise of ridinilazole to address an important public health need in CDI. Through our ongoing landmark Phase 3 clinical programme, we aim to show that our microbiome preserving antibiotic is superior in sustaining cures compared to the current standard of care and so has the potential to be the front-line treatment option for patients with CDI," said Mr Glyn Edwards, Chief Executive Officer of Summit. "We are pleased with the excellent working relationship that has been formed between us over the last two years and thank BARDA for its continuing support of ridinilazole." The total committed funding from the BARDA award under Contract No. HHS0100201700014C is now $53.6 million, with one final option remaining. The final option provides funding support for potential applications for marketing approvals of ridinilazole. The BARDA contract provides for a cost-sharing arrangement with the committed funding drawn down over a specified development period. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR). About C. difficile Infection C. difficile infection is a serious healthcare threat in hospitals, long-term care homes and increasingly in the wider community with over one million estimated cases of CDI annually in the United States and Europe. CDI is caused by an infection of the colon by the bacterium C. difficile, which produces toxins that cause inflammation and severe diarrhoea, and in the most serious cases can be fatal. Patients typically develop CDI following the use of broad-spectrum antibiotics that can cause widespread damage to the natural gastrointestinal (gut) flora and allow overgrowth of C. difficile bacteria. The vast majority of patients are treated with broad-spectrum antibiotics, which cause further damage to the gut flora and are associated with high rates of recurrent disease. Reducing disease recurrence is the key clinical issue in CDI as repeat episodes are typically more severe and associated with an increase in mortality rates and healthcare costs. A study estimated that the total costs attributable to the management of CDI were approximately $6.3 billion per year in the United States. About Ridinilazole Ridinilazole is an oral small molecule new mechanism antibiotic that is designed to selectively kill C. difficile, thereby preserving patients' protective gut microbiome and leading to sustained CDI cures. In a Phase 2 proof of concept trial in CDI patients, ridinilazole showed statistical superiority in sustained clinical response ('SCR') rates compared to the standard of care, vancomycin. In that trial, SCR was defined as clinical cure at end of treatment and no recurrence of CDI within 30 days of the end of therapy. Ridinilazole was also shown to be highly preserving of the gut microbiome in the Phase 2 proof of concept trial, which was believed to be the reason for the improved clinical outcome for the ridinilazole-treated patients. In addition, ridinilazole preserved the gut microbiome to a greater extent than the marketed narrow-spectrum antibiotic fidaxomicin in an exploratory Phase 2 clinical trial. Ridinilazole has received Qualified Infectious Disease Product ('QIDP') designation and has been granted Fast Track designation by the US Food and Drug Administration. The QIDP incentives are provided through the US GAIN Act and include a potential extension of marketing exclusivity for an additional five years upon FDA approval. About the Contract with BARDA This project has been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority, a component of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, under contract number HHS0100201700014C. About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc. Contacts Summit Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951 Michelle Avery (US office) +1 617 225 4455 Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880 Liam Murray / Tony Rawlinson N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000 Aubrey Powell / Jen Boorer, Corporate Finance Tom Salvesen, Corporate Broking Bryan Garnier & Co Limited (Joint Broker) Tel: +44 (0)20 7332 2500 Phil Walker / Dominic Wilson MSL Group (US) Tel: +1 781 684 6557 mailto:summit@mslgro |
Posted at 15/4/2019 07:20 by kirk 6 Released .....Summit Therapeutics plc Summit Presents In Vivo Proof Of Concept Data For New Mechanism Antibiotics Targeting Enterobacteriac...So |
Posted at 14/4/2019 14:51 by waterloo01 How unusual, a Sunday news release just in via email.Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019 Summit Therapeutics plc (‘Summit’ Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019 DDS-04 Series Cures Enterobacteriaceae Infection in Animal Model Potential in Lung, Bloodstream and Urinary Tract Infections Activity Shown Against Resistant and Non-Resistant Strains Enterobacteriaceae are Gram-Negative Bacteria that Cause a Large Number of Serious Infections Oxford, UK, and Cambridge, MA, US, 14 April 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today presented in vivo proof of concept data for the DDS-04 series of new mechanism antibiotics targeting Enterobacteriaceae in an oral session at the 29th European Congress of Clinical Microbiology & Infectious Diseases (‘ECCMID’ Enterobacteriaceae are a family of Gram-negative bacteria responsible for a large number of severe and often deadly infections. In the data presented, a DDS-04 series compound cured infection in a translationally-rele “Patients with Enterobacteriaceae infections are increasingly at risk for poor outcomes due to the spread of antimicrobial resistance,” said Dr David Roblin, President of R&D of Summit. “Mainstay treatments are losing their effectiveness, and patients do not have the luxury of time to fail antibiotic therapy. There is a pressing need for new, targeted Enterobacteriaceae antibiotics that can serve to improve patient outcomes.” The DDS-04 series acts via LolCDE, a novel bacterial target. The LolCDE site of DDS-04 series activity is conserved in the majority of therapeutically important Enterobacteriaceae, resulting in targeted spectrum compounds. With its new mechanism of action, the DDS-04 series was rapidly bactericidal and highly potent across globally diverse Enterobacteriaceae strains in research studies, which included multi-drug resistant isolates. Importantly, the DDS-04 series also showed low propensity for resistance development and did not show cross-resistance with existing classes of antibiotics, suggesting that DDS-04 compounds have the potential to overcome known resistance mechanisms. This profile makes the DDS-04 series attractive for further development for the treatment of Enterobacteriaceae infections. “The DDS-04 series aligns with our antibiotic strategy. There is a clear opportunity to improve patient outcomes and a need for new mechanisms to deliver these improved outcomes and also to help address the spread of antimicrobial resistance,” commented Mr Glyn Edwards, Chief Executive Officer of Summit. “We look forward to gathering further data to support the selection of a preclinical candidate from the DDS-04 series.” A copy of the presentation is available in the Publications section of the Company’s website: www.summitplc.com. About Enterobacteriaceae Enterobacteriaceae are a family of Gram-negative bacteria responsible for severe and often deadly infections. They account for a significant fraction of cases across conditions, including complicated urinary tract infections, bloodstream infections and hospital-acquired pneumonias. Summit estimates there are more than 1 million infections in the US annually caused by Enterobacteriaceae across these three settings. Increasing resistance of Enterobacteriaceae has rendered many marketed antibiotics ineffective against these bacteria. Two of the most alarming antibiotic resistance trends are extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and carbapenem-resistant Enterobacteriaceae (CRE). ESBL is an enzyme that allows bacteria to become resistant to a wide variety of penicillin and cephalosporin antibiotics. ESBL-producing Enterobacteriaceae account for an estimated 26,000 infections annually in the US with 1,700 deaths, according to the US Centers for Drug Control and Prevention (‘CDC’). CRE are resistant to nearly all existing antibiotics, including carbapenems which are considered the antibiotics of last resort. CRE account for an estimated 9,000 infections per year in the US and 600 deaths, according to the CDC. About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and ESKAPE pathogens and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc. |
Posted at 03/10/2018 15:14 by chrisatrdg Todays RNSSummit Therapeutics plc - SUMM Summit Highlights Phase 3-Ready Precision Antibiotic Ridinilazole at IDWeek 2018 Released 12:00 03-Oct-2018 Summit Therapeutics plc (‘Summit’ Summit Highlights Phase 3-Ready Precision Antibiotic Ridinilazole at IDWeek 2018 Ridinilazole in Development to Treat C. difficile Infection and Reduce Recurrent Disease Oxford, UK, and Cambridge, MA, US, 3 October 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, is highlighting ridinilazole’s potential as a front-line treatment for C. difficile infection (‘CDI’) in a series of oral and poster presentations at the infectious disease conference IDWeek 2018 in San Francisco, CA. Ridinilazole is the Company’s most advanced new mechanism antibiotic, which is expected to enter Phase 3 clinical trials in the first quarter of 2019. As are being outlined at IDWeek, the Phase 3 clinical trials of ridinilazole are designed not only to evaluate ridinilazole in the treatment of CDI but also to show its impact on reducing disease recurrence and in preserving the gut microbiome, important determinants of public health impact. The effectiveness of ridinilazole in the treatment of CDI and CDI recurrence will be evaluated by measuring sustained clinical response (‘SCR’), which is the primary endpoint for both of the two planned Phase 3 clinical trials. “We believe that to have success in antibiotics, we need to be bold and think differently. This is highlighted by our Phase 3 clinical trial design for ridinilazole that aims to show superiority of ridinilazole over vancomycin, the current standard of care. The primary endpoint will measure how ridinilazole can treat CDI and reduce recurrent CDI, the major unmet need in this disease. Finally, we are incorporating health economic outcomes measures that we believe will help support premium pricing,” commented Dr David Roblin, President of R&D of Summit. “If the Phase 3 clinical trial results are positive, we believe these measures would differentiate ridinilazole in CDI and support its front-line use.” A summary of the information being presented at IDWeek includes: Ridinilazole achieving statistical superiority over vancomycin in the primary endpoint of SCR in a Phase 2 clinical trial called CoDIFy; this superiority was driven by a large reduction in CDI recurrence. Ridinilazole significantly preserved the gut microbiome of patients with CDI in CoDIFy, which Summit believes led to the reduction in recurrent CDI. The design of the ridinilazole Phase 3 clinical trials called Ri-CoDIFy which will use the same primary endpoint of SCR. Ridinilazole’s activity is targeted to the site of infection. Preclinical studies and Phase 1 and 2 clinical trials of ridinilazole have shown negligible systemic exposure and levels of drug in the colon and/or faeces significantly above the minimum inhibitory concentration. A good safety profile with ridinilazole, being generally well tolerated in prior clinical trials and non-clinical studies. Ridinilazole was significantly more potent against over 500 recent clinical isolates of C. difficile than vancomycin and metronidazole, another commonly used CDI treatment, regardless of ribotype or antibiotic resistance profile. Diagnostics are important for selective antibiotics, such as ridinilazole, to ensure patients are treated with the right drug for their infection. As was used in CoDIFy, a test for the toxins produced by C. difficile will also be used in the Phase 3 clinical trials to confirm that patients have CDI. Copies of the presentations are available under the Publications section of Summit’s website, www.summitplc.com. About C. difficile Infection C. difficile infection is a serious healthcare threat in hospitals, long-term care homes and increasingly in the wider community with over one million estimated cases of CDI annually in the United States and Europe. CDI is caused by an infection of the colon by the bacterium C. difficile, which produces toxins that cause inflammation and severe diarrhoea, and in the most serious cases can be fatal. Patients typically develop CDI following the use of broad-spectrum antibiotics that can cause widespread damage to the natural gastrointestinal (gut) flora and allow overgrowth of C. difficile bacteria. Existing CDI treatments are predominantly broad-spectrum antibiotics, which cause further damage to the gut flora and are associated with high rates of recurrent disease. Reducing disease recurrence is the key clinical issue in CDI as repeat episodes are typically more severe and associated with an increase in mortality rates and healthcare costs. The economic impact of CDI is significant with one study estimating annual acute care costs at $4.8 billion in the US. About Ridinilazole Ridinilazole is a small molecule antibiotic that Summit is developing for the treatment of CDI. In preclinical efficacy studies, ridinilazole exhibited a targeted spectrum of activity that combined a potent bactericidal effect against all clinical isolates of C. difficile tested with minimal impact on other bacteria that are typically found in the gut microbiome. In a Phase 2 proof of concept trial in CDI patients, ridinilazole showed statistical superiority in sustained clinical response ('SCR') rates compared to the standard of care, vancomycin. In that trial, SCR was defined as clinical cure at end of treatment and no recurrence of CDI within 30 days of the end of therapy. Ridinilazole was also shown to be highly preserving of the gut microbiome in the Phase 2 proof of concept trial, which was believed to be the reason for the improved clinical outcome for the ridinilazole-treated patients. In addition, ridinilazole preserved the gut microbiome to a greater extent than the marketed narrow-spectrum antibiotic fidaxomicin in an exploratory Phase 2 clinical trial. Ridinilazole, an orally administered small molecule, has received Qualified Infectious Disease Product ('QIDP') designation and has been granted Fast Track designation by the US Food and Drug Administration. The QIDP incentives are provided through the US GAIN Act and include a potential extension of marketing exclusivity for an additional five years upon FDA approval. About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc. |
Posted at 06/9/2018 12:13 by chrisatrdg RNS TodaySummit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets Thu, 6 Sep 2018 12:00 Summit Therapeutics plc (donotreply-eu@globe To:you Details Summit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets Summit Therapeutics plc (‘Summit’ Summit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets Discovery Enabled by Discuva Platform and Proprietary Bacterial Libraries Oxford, UK, and Cambridge, MA, US, 6 September 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announced today the discovery of multiple new mechanism antibiotics against novel ESKAPE pathogen targets. Commonly referred to as superbugs, the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp.) collectively comprise the leading cause of hospital-acquired infections globally. New classes of antibiotics are urgently needed to address these pathogens that are increasingly developing resistance to existing antibiotic drug classes. “We believe we are building a very different antibiotics company that focuses on bringing innovation to an area of high unmet need. With new science, we believe the threat of ESKAPE pathogens and other serious infectious diseases can potentially be solved,” commented Mr Glyn Edwards, Chief Executive Officer of Summit. “At the core of our innovation is our powerful Discuva Platform. The platform allows us to uncover possible new ways to combat the potentially deadly ESKAPE pathogens. We can then aim to exploit this knowledge through the discovery and development of targeted new mechanism antibiotics.” Summit’s Discuva Platform utilises proprietary libraries of mutant bacteria to identify genes which are essential for bacteria to survive. Summit’s libraries provide coverage across the ESKAPE pathogens. Through the Discuva Platform, Summit has identified essential ESKAPE pathogen genes, which could represent novel drug targets against these pathogens. Several of these targets are now the focus of Summit’s drug development programmes, with the platform having already discovered potential new mechanism antibiotics against them. “We believe the identification of novel targets gives us the potential to develop the right drugs for the right bacteria, infection and patient. That would enable us to ensure that our antibiotics truly meet the needs of patients, their treating physicians and healthcare providers and to promote antibiotic stewardship,” added Dr David Roblin, President of R&D of Summit. “We believe this approach will afford us the opportunity to replace the current standards of care for these serious infections caused by the ESKAPE pathogens and bring potentially life-saving treatments to patients.” About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR). Contacts Summit Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951 Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455 Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880 Liam Murray / Tony Rawlinson N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000 Aubrey Powell / Jen Boorer, Corporate Finance Tom Salvesen, Corporate Broking Panmure Gordon (Joint Broker) Tel: +44 (0)20 7886 2500 Freddy Crossley, Corporate Finance James Stearns, Corporate Broking MSL Group (US) Tel: +1 781 684 6557 Jon Siegal summit@mslgroup.com Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700 Mary-Jane Elliott / Jessica Hodgson / summit@consilium-com Lindsey Neville Summit Forward-looking Statements Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the potential benefits of the CARB-X award, including whether the option segments will be exercised, the clinical and preclinical development of the Company’s product candidates, the therapeutic potential of the Company’s product candidates, the potential commercialisation of the Company’s product candidates, the sufficiency of the Company’s cash resources, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that the Company makes with the Securities and Exchange Commission, including the Company’s Annual Report on Form 20-F for the fiscal year ended 31 January 2018. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release. -END- |
Posted at 05/9/2018 12:10 by chrisatrdg RNSRegulatory Story Go to market news section View chart Print Summit Therapeutics plc - SUMM Summit Nominates New Mechanism Antibiotic SMT-571 as its Lead Clinical Candidate for the Treatment of Gonorrhoea Released 12:00 05-Sep-2018 Summit Therapeutics plc (‘Summit’ Summit Nominates New Mechanism Antibiotic SMT-571 as its Lead Clinical Candidate for the Treatment of Gonorrhoea SMT-571 Designed to Exploit Novel N. gonorrhoeae Target Identified by Discuva Platform Details Presented at ESCMID/ASM Conference New Corporate Website Launched Highlighting Summit’s Antibiotic Innovation Oxford, UK, and Cambridge, MA, US, 5 September 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today announces that it has nominated SMT-571 as its lead clinical candidate from its first gonorrhoea series. New mechanism antibiotics are important in the fight against gonorrhoea, as the pathogen is becoming increasingly resistant to the only recommended treatment option. Just last week, the US Centers for Disease Control and Prevention (‘CDC’) reported preliminary data that gonorrhoea cases in the US increased by 67% between 2013 and 2017 and with resistant cases on the rise, the CDC stated that additional treatment options for gonorrhoea are urgently needed. In in vitro studies, SMT-571 killed N. gonorrhoeae through a novel target involved in cell division, which was identified using Summit’s Discuva Platform. SMT-571 has demonstrated potent in vitro activity against clinical isolates of N. gonorrhoeae, including multi-drug resistant strains. With the nomination, Summit is progressing SMT-571 into investigational new drug (‘IND’)- “We believe our new science and new way of thinking together enable our goal to develop the right drug for the right pathogen and create opportunities for success,” said Dr David Roblin, President of R&D of Summit. “SMT-571 is being developed specifically for gonorrhoea, meaning that it is designed to have both a targeted spectrum of activity and be tailored to meet the needs of patients with gonorrhoea.” SMT-571 is designed to be an oral treatment for gonorrhoea and to have activity across the three sites of gonorrhoea infection: genital, rectal and pharyngeal. Details of SMT-571 are being presented at the ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance taking place 4-7 September in Lisbon, Portugal. A copy of the poster is available in the Publications section of the Company’s website, www.summitplc.com. In addition, Summit launched a new corporate website today at www.summitplc.com to highlight the Company’s innovation in antibiotics, including its gonorrhoea programme. About Gonorrhoea It is estimated by the World Health Organization (‘WHO’) that there are approximately 78 million new cases of gonorrhoea globally per year. Neisseria gonorrhoeae has consistently developed resistance to each class of antibiotics recommended for treatment and there is now only one treatment recommended by the CDC, a combination of two antibiotics. There are currently no other recommended antibiotics that can be effectively deployed to target the disease. The WHO ranks as “High” the priority of R&D investment into the search for antibiotics which are effective against Neisseria gonorrhoeae and in August 2018, the CDC stated that in light of increased problems with resistance, additional treatment options were urgently required. About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR). The development of SMT-571 is supported by the Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and by an award from Wellcome Trust. The contents of this announcement are solely the responsibility of the authors and do not necessarily represent the official views of the HHS Office of the Assistant Secretary for Preparedness and Response, Wellcome Trust, CARB-X or its funders. Contacts Summit Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951 Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455 Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880 Liam Murray / Tony Rawlinson N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000 Aubrey Powell / Jen Boorer, Corporate Finance Tom Salvesen, Corporate Broking Panmure Gordon (Joint Broker) Tel: +44 (0)20 7886 2500 Freddy Crossley, Corporate Finance James Stearns, Corporate Broking MSL Group (US) Tel: +1 781 684 6557 Jon Siegal summit@mslgroup.com Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700 Mary-Jane Elliott / Jessica Hodgson / summit@consilium-com Lindsey Neville Summit Forward-looking Statements Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the potential benefits of the CARB-X award, including whether the option segments will be exercised, the clinical and preclinical development of the Company’s product candidates, the therapeutic potential of the Company’s product candidates, the potential commercialisation of the Company’s product candidates, the sufficiency of the Company’s cash resources, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that the Company makes with the Securities and Exchange Commission, including the Company’s Annual Report on Form 20-F for the fiscal year ended 31 January 2018. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release. -END- CLOSE |
Posted at 06/8/2018 13:49 by kirk 6 Summit Therapeutics plc Summit Therapeutics To Present At The Canaccord Genuity Growth ConferenceSource: UK Regulatory (RNS & others) TIDMSUMM Summit Therapeutics plc ("Summit", or the "Company") Summit Therapeutics to Present at the Canaccord Genuity Growth Conference Oxford, UK, and Cambridge, MA, US, 6 August 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Glyn Edwards, Chief Executive Officer, will present at the Canaccord Genuity Growth Conference on 9 August 2018 at 8:00am EDT in Boston. A live audio webcast of the presentation will be available through the Investors section on the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation. About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc. For more information, please contact: Summit Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951 Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455 Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880 Liam Murray / Tony Rawlinson N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000 Aubrey Powell / Jen Boorer Panmure Gordon (Joint Broker) Tel: +44 (0)20 7886 2500 Freddy Crossley, Corporate Finance James Stearns, Corporate Broking MSL Group (US) Tel: +1 617 684 6557 Jon Siegal Jon.siegal@mslgroup. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
